Print

Baxter International, Inc. (BAX) to Initiate Late-Stage Clinical Trial of BAX 855 for the Treatment of Hemophilia A  
1/7/2013 10:27:55 AM

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced it has submitted an Investigational New Drug (IND) application for its investigational hemophilia A treatment BAX 855 with the U.S. Food and Drug Administration, following positive results from a Phase I trial. BAX 855 is a full-length longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] – the most widely chosen rFVIII in the world. Baxter expects to start enrollment of adult patients in its Phase II/III study in the first quarter of 2013.
//-->